Potential of aromatase inhibitors for ovulation and superovulation induction in infertile women

Drugs

Volumn 66, Issue 17, 2006, Pages 2149-2160

  Mitwally, Mohamed F M ^a,b   Casper, Robert F ^c,d  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; CLOMIFENE CITRATE; ESTROGEN; EXEMESTANE; FADROZOLE; FOLLITROPIN; FORMESTANE; GONADOTROPIN; HYDROCORTISONE; LETROZOLE; TAMOXIFEN; VOROZOLE;

BREAST CANCER; CANCER SURVIVOR; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIAL DISEASE; ENDOMETRIOSIS; ESTROGEN BLOOD LEVEL; FEMALE INFERTILITY; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; LEG CRAMP; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE PREGNANCY; NAUSEA AND VOMITING; NONHUMAN; OPTIMAL DRUG DOSE; OVULATION; PREGNANCY OUTCOME; PREMENSTRUAL SYNDROME; REVIEW; SINGLE DRUG DOSE; SUPEROVULATION; TERATOGENESIS; TREATMENT OUTCOME; UTERINE CERVIX DISEASE;

ANOVULATION; AROMATASE INHIBITORS; FEMALE; HUMANS; INFERTILITY, FEMALE; OVULATION; OVULATION INDUCTION; SUPEROVULATION;

EID: 33845340127     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666170-00001     Document Type: Review

References (47)

1. Greenblatt RB, Barfield WE, Jungck EC, et al. Induction of ovulation with MRL/41. JAMA 1961; 178: 101-5
2. Mitwally MFM, Casper RF. Aromatase inhibition: a novel method of ovulation induction in women with polycystic ovarian syndrome. Reprod Technol 2000; 10: 244-7
3. Mitwally MFM, Casper RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril 2002; 774: 776-80
4. Mitwally MF, Casper RF. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod 2003; 188: 1588-97
5. Mitwally MF, Casper RF. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynecol Investig 2004; 11: 406-15
6. Mitwally MFM, Casper RF. Single dose administration of the aromatase inhibitor, letrozole: a simple and convenient effective method of ovulation induction. Fertil Steril 2005; 83: 229-31
7. Mitwally MF, Biljan MM, Casper RF. Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. Am J Obstet Gynecol 2005; 192: 381-6
8. Sammour A, Biljan MM, Tan SL, et al. Prospective randomized trial comparing the effects of letrazole (LE) and clomiphene citrate (CC) on follicular development, endometrial thickness and pregnancy rate in patients undergoing super-ovulation prior to intrauterine insemination (IUI). Fertil Steril 2001; 76: S110
9. Fatemi HM, Kolibianakis E, Tournaye H, et al. Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reprod Biomed Online 2003; 75: 543-6
10. Healey S, Tan SL, Tulandi T, et al. Effects of letrozole on superovulation with gonadotropins in women undergoing intrauterine insemination. Fertil Steril 2003; 806: 1325-9
11. Al-Fadhli R, Sylvestre C, Buckett W, et al. A randomized trial of superovulation with two different doses of letrozole. Fertil Steril 2006; 85: 161-4
12. Al-Omari WR, Sulaiman WR, Al-Hadithi N. Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome. Int J Gynaecol Obstet 2004; 853: 289-91
13. Al-Fozan H, Al-Khadouri M, Tan SL, et al. A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertil Steril 2004; 82: 1561-3
14. Goswami SK, Das T, Chattopadhyay R, et al. A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report. Hum Reprod 2004; 19: 2031-5
15. Cortinez A, De Carvalho I, Vantman D, et al. Hormonal profile and endometrial morphology in letrozole-controlled ovarian hyperstimulation in ovulatory infertile patients. Fertil Steril 2005; 83: 110-5
16. Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23: 4347-53
17. Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol 2005; 23: 3858-9
18. Garcia-Velasco JA, Moreno L, Pacheco A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril 2005; 84: 82-7
19. Ryan GL, Moss V, Davis WA, et al. Oral ovulation induction agents combined with low-dose gonadotropin injections and intrauterine insemination: cost- and clinical effectiveness. J Reprod Med 2005; 50: 943-50
20. Bayar U, Tanrierdi HA, Barut A, et al. Letrozole vs. clomiphene citrate in patients with ovulatory infertility. Fertil Steril 2006; 85: 1045-8
21. Elnashar A, Fouad H, Eldosoky M, et al. Letrozole induction of ovulation in women with clomiphene citrate-resistant polycystic ovary syndrome may not depend on the period of infertility, the body mass index, or the luteinizing hormone/follicle-stimulating hormone ratio. Fertil Steril 2006; 85: 161-4
22. Atay V, Cam C, Muhcu M, et al. Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Int Med Res 2006; 34: 73-6
23. Sohrabvand F, Ansari S, Bagheri M. Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease. Hum Reprod 2006; 21: 1432-5
24. Cole PA, Robinson CH. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 1999; 33: 2933-44
25. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001; 7: 2620-35
26. Mauras N, Lima J, Patel D, et al. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. J Clin Endocrinol Metab 2003; 88: 5951-6
27. Mitwally MFM, Casper RF. Aromatase inhibition for ovarian stimulation: future avenues for infertility management. Curr Opin Obstet Gynecol. 2002; 14: 255-63
28. Mitwally MFM, Casper RF. Aromatase inhibitors for the treatment of infertility. Expert Opin Investig Drugs. 2003; 12: 353-71
29. Mitwally MFM, Casper RF. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 2006; 91: 760-71
30. Naftolin F, MacLusky NJ, Leranth CZ, et al. The cellular effects of estrogens on neuroendocrine tissues. J Steroid Biochem 1988; 30: 195-07
31. Roberts V, Meunier H, Vaughan J, et al. Production and regulation of inhibin subunits in pituitary gonadotropes. Endocrinology 1989; 124: 552-4
32. Mason AJ, Berkemeier LM, Schmelzer CH, et al. Activin B: precursor sequences, genomic structure and in vitro activities. Mol Endocrinol 1989; 3: 1352-8
33. Mitwally MFM, Casper RF. Letrozole for ovulation induction. Exp Rev Obstet Gynecol 2006; 1 (1): 15-27
34. Weil SJ, Vendola K, Zhou J, et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 1989; 837: 2479-85
35. Weil S, Vendola K, Zhou J, et al. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 1999; 848: 2951-6
36. Vendola KA, Zhou J, Adesanya OO, et al. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998; 101: 2622-9
37. Vendola K, Zhou J, Wang J, et al. Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol Reprod 1999; 612: 353-7
38. Giudice LC. Insulin-like growth factors and ovarian follicular development. Endocr Rev 1992; 13: 641-69
39. Mitwally MFM, Casper RF, Diamond MP. The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment. Reprod Biol Endocrinol 2005; 4: 3-54
40. Hamilton A, Piccart M. The third-generation nonsteroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 1999; 10: 377-84
41. Goss PE. Risks versus benefits in the clinical application of aromatase inhibitors. Endocr Relat Cancer 1999; 6: 325-32
42. Palter SF, Tavares AB, Hourvitz A, et al. Are estrogens of import to primate/human ovarian folliculogenesis? Endocr Rev 2001; 223: 389-424
43. Tiboni GM. Aromatase inhibitors and teratogenesis. Fertil Steril 2004; 81: 1158-9
44. Biljan MM, Hemmings R, Brassard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins [abstract no. 1033]. Fertil Steril 2005; 84 Suppl. 1: 231
45. Tulandi T, Al-Fadhli R, Kabli N, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 2006; 85: 1761-5
46. Hoffman JI. Incidence of congenital heart disease: I. Postnatal incidence. Pediatr Cardiol 1995; 16: 103-13
47. Tredway DR, Buraglio M, Hemsey G, et al. A phase I study of the pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose anastrozole in healthy, premenopausal female volunteers. Fertil Steril 2004; 82: 1587-93